Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy